124 related articles for article (PubMed ID: 27205888)
1. Fabry disease: will markers of early disease enable early treatment and better outcomes?
Hughes DA
Curr Opin Cardiol; 2016 Jul; 31(4):434-9. PubMed ID: 27205888
[TBL] [Abstract][Full Text] [Related]
2. Fabry disease: a review of current management strategies.
Mehta A; Beck M; Eyskens F; Feliciani C; Kantola I; Ramaswami U; Rolfs A; Rivera A; Waldek S; Germain DP
QJM; 2010 Sep; 103(9):641-59. PubMed ID: 20660166
[TBL] [Abstract][Full Text] [Related]
3. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
4. [The neurological manifestations of Fabry disease. A review].
Firsov KV; Kotov AS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9):98-105. PubMed ID: 27735906
[TBL] [Abstract][Full Text] [Related]
5. [Cardiological follow-up in patients with Fabry disease].
Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
[TBL] [Abstract][Full Text] [Related]
6. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
[TBL] [Abstract][Full Text] [Related]
7. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
8. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
[TBL] [Abstract][Full Text] [Related]
9. [Fabry disease].
Kantola I; Penttinen M; Nuutila P; Viikari J
Duodecim; 2012; 128(7):729-39. PubMed ID: 22612023
[TBL] [Abstract][Full Text] [Related]
10. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
11. The management and treatment of children with Fabry disease: A United States-based perspective.
Hopkin RJ; Jefferies JL; Laney DA; Lawson VH; Mauer M; Taylor MR; Wilcox WR;
Mol Genet Metab; 2016 Feb; 117(2):104-13. PubMed ID: 26546059
[TBL] [Abstract][Full Text] [Related]
12. [Clinical efficacy of enzyme replacement therapy in Fabry disease. A critical review].
Lidove O; Papo T
Rev Med Interne; 2009 Oct; 30(10):920-9. PubMed ID: 19524334
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
14. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
[TBL] [Abstract][Full Text] [Related]
15. Long Term Treatment with Enzyme Replacement Therapy in Patients with Fabry Disease.
Oder D; Nordbeck P; Wanner C
Nephron; 2016; 134(1):30-6. PubMed ID: 27576727
[TBL] [Abstract][Full Text] [Related]
16. Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy.
Kovacevic-Preradovic T; Zuber M; Attenhofer Jost CH; Widmer U; Seifert B; Schulthess G; Fischer A; Jenni R
Eur J Echocardiogr; 2008 Nov; 9(6):729-35. PubMed ID: 18490303
[TBL] [Abstract][Full Text] [Related]
17. Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.
Lenders M; Stypmann J; Duning T; Schmitz B; Brand SM; Brand E
J Am Soc Nephrol; 2016 Jan; 27(1):256-64. PubMed ID: 25933799
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
Talbot AS; Lewis NT; Nicholls KM
Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
[TBL] [Abstract][Full Text] [Related]
19. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
[TBL] [Abstract][Full Text] [Related]
20. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--the Fabry Outcome Survey.
Hughes DA; Barba Romero MÁ; Hollak CE; Giugliani R; Deegan PB
Mol Genet Metab; 2011 Jul; 103(3):207-14. PubMed ID: 21543245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
